人黑色素瘤细胞WM451LU

细胞名称

人黑色素瘤细胞WM451LU

货物编码

BFN60808831

产品规格

T25培养瓶x1

1.5ml冻存管x2

细胞数量

1x10^6

1x10^6

保存温度

37℃

-198℃

运输方式

常温保温运输

干冰运输

安全等级

1

用途限制

仅供科研   3类

培养体系

90%DMEM+10%FBS+1%三抗

培养温度

37℃

二氧化碳浓度

5%

简介

人黑色素瘤细胞WM451LU取自22岁男性供体。该细胞源于ATCC

注释

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: COSMIC cell lines project.

Part of: Wistar Institute melanoma cell line collection.

Doubling time: 72 hours (PubMed=2253310).

Microsatellite instability: Stable (MSS) (PubMed=31068700; Sanger).

Omics: Array-based CGH.

Omics: Deep exome analysis.

Omics: DNA methylation analysis.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018. The major changes were: CSF1PO: 11,12->12, D18S51: 10->10,13, D5S818: 11,12->12, D7S820: 9,10->10 and FGA: 21->21,25.

基因突变

Heterozygous for BRAF p.Val600Glu (c.1799T>A) (ClinVar=VCV000013961) (PubMed=17260012; PubMed=18632627; PubMed=21156289; PubMed=23851445; Wistar).

CDKN2A p.Glu61fs*59 (c.179dupC) (p.Gly75fs; c.222dupC) (PubMed=23851445).

TP53 p.Tyr220Cys (c.659A>G) (ClinVar=VCV000127819) (PubMed=17260012; PubMed=21156289; PubMed=23851445).

HLA信息

Class I

HLA-A        A*24:02,24:02

HLA-B        B*07:02,07:02

Class II

HLA-DP        DPB1*06:01,06:01

HLA-DQ        DQB1*06:04,06:04

HLA-DR        DRB1*13:01,13:01

STR信息

Amelogenin        X

CSF1PO        12

D2S1338        18,19

D3S1358        18

D5S818        12

D7S820        9,10 (ATCC; ESTDAB)

10 (Cosmic-CLP; Wistar)

D8S1179        13,14

D13S317        11

D16S539        13

D18S51        10,13

D19S433        13

D21S11        28,31.2

FGA        21,25

TH01        9

TPOX        8,10

vWA        14,15

参考文献

PubMed=24055054; DOI=10.1016/j.celrep.2013.08.023

Villanueva J., Infante J.R., Krepler C., Reyes-Uribe P., Samanta M., Chen H.-Y., Li B., Swoboda R.K., Wilson M., Vultur A., Fukunaga-Kalabis M., Wubbenhorst B., Chen T.Y., Liu Q., Sproesser K., DeMarini D.J., Gilmer T.M., Martin A.-M., Marmorstein R., Schultz D.C., Speicher D.W., Karakousis G.C., Xu W., Amaravadi R.K., Xu X., Schuchter L.M., Herlyn M., Nathanson K.L.

Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.

Cell Rep. 4:1090-1099(2013)

PubMed=25056119; DOI=10.1158/0008-5472.CAN-14-1232-T

Watson I.R., Li L., Cabeceiras P.K., Mahdavi M., Gutschner T., Genovese G., Wang G., Fang Z., Tepper J.M., Stemke-Hale K., Tsai K.Y., Davies M.A., Mills G.B., Chin L.

The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF.

Cancer Res. 74:4845-4852(2014)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)